EU-supported COVAX Facility approves delivery of Pfizer/BioNTech COVID-19 vaccine to Ukraine

Photo: European Union
Photo: European Union

On 30 January, the EU-supported COVAX Facility decided to allocate 117,000 doses of Pfizer/BioNTech COVID-19 vaccine to Ukraine. Team Europe – including the European Commission, the European Investment Bank and Member States – has so far announced contributions of more than €870 million to COVAX.

“Vaccination is central to ending the pandemic. No one is safe until everyone is safe,” said Ambassador Matti Maasikas, Head of the EU Delegation to Ukraine. “In line with the Team Europe spirit, the EU is proud to support COVAX in delivering vaccines to our partners, and Ukraine is among the first of them.”

The European Union is working to support the launch of the vaccination campaign in Ukraine in February, together with Ukraine’s other international partners. The vaccine delivered via COVAX through this first assistance to Ukraine has been authorised in the EU by the European Medicines Agency. We welcome the government’s approach to first offer vaccination to people at risk, such as medical workers treating COVID-19 patients,” said the press release published by the European Union Delegation to Ukraine.

The European Union has mobilised a190 million package to assist Ukraine in the fight against the COVID-19 crisis, delivering medical material and equipment, providing support to strengthen the health system and economic recovery, as well as supporting vulnerable groups.

COVAX is a global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines.

Find out more

Press release

EU Support for COVAX